During 1965-2012, the prevalence of cigarette smoking among adults (aged ≥18 years) in the United States decreased from 42.4% to 18.1%, partly because of increases in smoking cessation (1, 2) . Quitting smoking is beneficial to health at any age, and cigarette smokers who quit before age 35 have premature mortality rates similar to those of persons who never smoked (1, 2) . To assess progress made toward the Healthy People 2020 target of increasing the proportion of U.S. adult cigarette smokers who made a quit attempt during the past year to ≥80% (objective TU-4.1),* CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) for the years 2001-2010 and 2011-2013 to provide updated state-specific trends in quit attempts among adult smokers (survey methodology changes required separate analysis of 2011-2013). During 2001-2010, the proportion of smokers who reported a quit attempt during the preceding 12 months increased in 29 states and the U.S. Virgin Islands. During 2011-2013, quit attempts increased in Hawaii and Puerto Rico and decreased in New Mexico. In 2013, past year quit attempts were reported most frequently by smokers in Puerto Rico and Guam (76.4%) and least frequently by those in Kentucky (56.2%). In every state, older smokers were generally less likely to report a past year quit attempt than were younger smokers.
Evaluating variation in health risk behaviors and the use of health services is needed to develop interventions and promotion strategies that address public health at multiple levels (2, 3) . Proven interventions that increase cessation are important for reducing smoking-related morbidity and mortality and include mass media campaigns, telephone-based tobacco cessation services (quitlines), higher prices for tobacco products, comprehensive smoke-free laws, better health insurance coverage of effective cessation treatments, and health systems changes to integrate tobacco dependence treatment into routine clinical care (1, 3) . The findings in this report support previous findings on variations in quit attempts among states (2) and underscore the continued need for surveillance and evaluation of health risk behaviors to guide preventive health care services (1) (2) (3) .
The BRFSS is an ongoing, state-based, random-digit-dialed telephone survey of the noninstitutionalized, civilian population aged ≥18 years conducted annually in all 50 states, the District of Columbia (DC), Guam, Puerto Rico, and the U. In 2011, BRFSS added cellular (wireless-only) telephone households to the survey and the sample weighting methodology was updated to accommodate declining response rates and to maintain a representative sample for the U.S. population (4) . Because of this change in methodology, data from 2001-2010 and those from 2011-2013 were analyzed separately.
Past year quit attempts of ≥1 day among current smokers (persons who had smoked ≥100 cigarettes during their lifetime and currently smoked "every day" or "some days") were assessed for the years 2001-2010; for the years 2011-2013, past year quit attempts were assessed for both current and former smokers (persons who had smoked ≥100 cigarettes in their lifetime, but did not currently smoke).
The percentage of smokers making quit attempts § and 95% confidence intervals were calculated for survey years 2001 . For 2001 , multivariable logistic regression was used to analyze linear trends in quit attempts for each state, DC, Puerto Rico, and the U.S. Virgin Islands, controlling for sex, age, and race/ethnicity. The Wald chi-square test was used to test for statistical significance (p<0.05). For 2011-2013, differences in quit attempts were determined from non-overlapping 95% confidence intervals, because there were too few years to support regression modeling. Quit attempt proportions by age groups were calculated for years 2011-2013 combined.
In 2013, approximately two thirds of all adult smokers surveyed reported that they had attempted to quit or did quit in the past year (median = 65.9%), with the proportion making a quit attempt ranging from 56.2% (Kentucky) to 76.4% (Puerto Rico and Guam) ( Table 1) . During 2001-2010, there was a significant linear increase in the proportion of adult cigarette smokers who had made a quit attempt in the past year in 29 states and the U.S. Virgin Islands (Figure) . The median was 56.1% in 2001 and 58.8% in 2010. During 2011-2013, the proportion who had made a quit attempt increased in Hawaii and Puerto Rico and decreased in New Mexico.
During 2011-2013, across all states and DC, the proportion of smokers who reported they had made a quit attempt generally was lower among older respondents ( Table 2 ). The median proportion who had made a quit attempt across states among persons aged 18-24 years, 25-44 years, 45-64 years, and ≥65 years was 73.2%, 68.7%, 60.9%, and 56.4%, respectively. With the exception of smokers in Montana aged ≥65 years (49.8%), more than half of smokers, regardless of age group, reported having tried to quit in the past year. Jurisdictions with the highest proportion of respondents reporting having made a quit attempt by age group were DC (18-24 years, 83.5%), Florida (25-44 years, 74.6%), and New York (45-64 years, 68.6%, and ≥65 years, 68.0%). States with the lowest proportion of respondents reporting having made a quit attempt by age group were Maryland (18-24 years, 62.6%), West Virginia § Only current smokers with an unsuccessful quit attempt in the past 12 months were included in calculating quit attempts for 2001-2010; former smokers who had quit in the past year were not included because until 2009, former smokers were not asked when they had last smoked.
(25-44 years, 57.1%), Nevada and South Dakota (45-64 years, 52.9%), and Montana (≥65 years, 49.8%).
Discussion
During 2001-2010, the proportion of adult cigarette smokers who had made a quit attempt in the past year increased linearly in 29 states and the U.S. Virgin Islands; during 2011-2013, this proportion increased in Hawaii and Puerto Rico and decreased in New Mexico. During 2011-2013, a majority of smokers in all age groups tried to quit in almost all states, although the proportion of smokers who attempted to quit decreased with increasing age. In 2013, approximately two thirds of smokers had made a quit attempt in the past year, although state proportions ranged from 56.2% to 76.4%. These results reflect the importance of ongoing state-based surveillance and evaluation in examining state variations and identifying health issues and disparities (2, 3) . These data can help states to develop health promotion and prevention programs and to monitor their progress in tobacco control.
Helping tobacco users to quit can reduce tobacco-related disease, death, and health care costs (1, 3) . Increasing taxes on tobacco products, passing and implementing indoor smokefree laws, improving health insurance coverage of cessation services, and integrating tobacco dependence treatment into routine clinical care have all helped increase cessation rates (1, 3) . State per capita tobacco control program expenditures are one measure of the state's ability to implement effective tobacco control program components, including smoking cessation interventions; in the past decade, states with the highest expenditures have had the greatest declines in cigarette smoking (1, 3, 5) . As part of CDC's National Tobacco Control Program, all states are funded to work toward implementation of comprehensive tobacco control programs that comprise evidencebased strategies to increase smoking cessation, including mass media campaigns with graphic anti-smoking ads, such as the Tips from Former Smokers (Tips) campaign. ¶ Tips profiles former smokers who are living with serious long-term health effects from smoking and secondhand smoke exposure, and refers smokers who want help quitting to the national toll-free portal number, 1-800-QUIT-NOW. During the first phase of the campaign (March 19-June 10, 2012), calls to the quitline increased and resulted in an additional 1.6 million smokers making a quit attempt (1, 6) .
Variations by states in the proportion of cigarette smokers who reported having made a quit attempt in the past year might be attributed to a number of factors, including differences in population demographics; tobacco control program infrastructure, programs, and policies; and awareness, availability, accessibility, and use of smoking cessation treatments (1, 3, 7) . Nationally, younger persons, African Americans, and Abbreviation: CI = confidence interval. * Persons aged ≥18 years who reported having stopped smoking for ≥1 day during the past 12 months because they were trying to quit smoking and were current smokers during time of interview or former smokers who quit during the past year. Data were weighted to be representative of the state and territory population.
those with higher than a high school diploma were more likely to report a quit attempt in the past year than were older persons, whites, and those with less education (1, 8) . With the requirement by the Patient Protection and Affordable Care Act** that non-grandfathered private insurance plans cover FDA-approved cessation medications, † † access to effective cessation treatments is anticipated to increase. The findings in this report are subject to at least four limitations. First, only current smokers with an unsuccessful quit attempt in the preceding 12 months were included in the 2001-2010 analysis; therefore, the 2001-2010 data do not provide a complete representation of total past-year quit attempts. Second, during 2001-2010, U.S. adults with wireless-only service (24.5%) were not included in the survey, although they are twice as likely to smoke cigarettes as the rest of the population (9) . Because wireless-only households tend to be a younger demographic and younger persons are more likely to report a quit attempt (1), these data might underestimate actual quit attempts in some states. Third, modeling was limited to linear trends; it is possible that trends for some states are nonlinear. Finally, the median response rate for 2001-2013 ranged from 41.2% to 54.6%. While lower response rates can increase the potential for bias, national estimates from state-aggregated BRFSS data have been shown to be roughly comparable with smoking estimates from other surveys with higher response rates (9, 10) .
Examination of state variations can be used to identify effective public health programs and guide programs, promotions, and policies (2, 3) . To increase the number of cessation attempts, state tobacco control programs can focus their cessation activities on promoting health systems changes that make screening and treatment for tobacco use the standard of care in clinical settings; improving insurance coverage of evidence-based cessation treatments and promoting their use; and increasing use of state quitlines with mass media campaigns that contain graphic anti-smoking ads, such as Tips (3). Other effective interventions for increasing quit attempts and cessation include increasing the unit price of tobacco products and making workplaces and public places smoke-free (1,3). Sustained, comprehensive state tobacco control programs with adequate infrastructure and funded at CDC-recommended levels can accelerate progress toward increasing tobacco cessation and reducing tobacco-related diseases and deaths in the United States (3).
Summary
What is already known on this topic?
Quitting smoking is beneficial to health at any age, and cigarette smokers who quit before age 35 years have mortality rates similar to those of persons who never smoked.
What is added by this report?
During 2001-2010, the proportion of adult cigarette smokers who had made a quit attempt in the past year increased significantly in 29 states and the U.S. Virgin Islands. During 2011-2013, the proportion who had made a quit attempt increased in Hawaii and Puerto Rico and decreased in New Mexico. In 2013, the proportion who had made a quit attempt ranged from 56.2% (Kentucky) to 76.4% (Puerto Rico and Guam) with a median of 65.9%, and was generally lower in older age groups.
What are the implications for public health practice?
Continued implementation of effective evidence-based public health interventions can reduce the health and costs impacts of smoking-related disease and death and accelerate progress toward meeting the Healthy People 2020 target to increase to ≥80% the proportion of U.S. adult cigarette smokers who made a quit attempt in the past year. These interventions include increasing the price of tobacco products, implementing comprehensive smoke-free laws, conducting educational mass media campaigns, and providing insurance coverage for all effective cessation treatments as well as access to quitlines. Since 2010, the proportion of U.S. 12th grade students who used marijuana during the preceding 30 days (21.4%) has surpassed the proportion who used cigarettes (19.2%).* Negative outcomes associated with cigarette and marijuana use include addiction to one or both substances and diminished cognitive function, which can lead to lower academic achievement (1, 2) . Moreover, concurrent use of tobacco and marijuana could thwart prevention and cessation efforts for both products (1) . CDC analyzed data from the 1997-2013 national Youth Risk Behavior Surveys (YRBS) among U.S. non-Hispanic white (white), non-Hispanic black (black), and Hispanic students in grades 9-12 to examine trends in the prevalence of current 1) exclusive cigarette or cigar use, 2) exclusive marijuana use, and 3) any use of the three products. CDC further examined the prevalence of current marijuana use among current users of cigarettes or cigars. During 1997-2013, exclusive cigarette or cigar use declined overall by 64%, from 20.5% to 7.4% (p<0.01). However, exclusive marijuana use more than doubled overall from 4.2% to 10.2% (p<0.01). Any cigarette, cigar, or marijuana use decreased overall from 46.1% to 29.9% (p<0.01), whereas marijuana use among cigarette or cigar users increased from 51.2% to 62.4%. Considerable increases were identified among black and Hispanic students toward the end of the study period for exclusive marijuana use and marijuana use among cigarette or cigar users. Increased exclusive marijuana use and use of marijuana among cigarette or cigar users could undermine success in reducing tobacco use among youths. Closer collaboration between public health professionals to address prevention of tobacco and marijuana use might be beneficial in the development of evidence-based policies and programs to prevent tobacco and marijuana use.
The national YRBS is a biennial cross-sectional survey of U.S. public and private school students in grades 9-12, administered in a classroom setting using a paper and pencil questionnaire. CDC examined trends in the prevalence of current 1) exclusive use of cigarettes or cigars; 2) exclusive use of marijuana; and 3) any use of cigarettes, cigars, or marijuana among white, black, and Hispanic students. CDC also examined the prevalence of current marijuana use among current users of cigarettes or cigars. Records with missing data for cigarette use, cigar use, marijuana use, race/ethnicity, or sex, were excluded from the analysis. The analytic data set was further restricted to students self-identifying as black, white, or Hispanic, resulting in final analytic sample sizes ranging from 11,050 (2013) to 13,242 (2009). † Current use was defined as smoking cigarettes or cigars on ≥1 days, or using marijuana one or more times, during the 30 days preceding the survey. § Exclusive cigarette or cigar use was defined as current use of cigarettes or cigars, but not marijuana. Exclusive marijuana use was defined as current use of marijuana, but not cigarettes or cigars. Any cigarette, cigar, or marijuana use was defined as current use of any of the three products. Among current cigarette or cigar users, the proportion of current marijuana users was assessed. Trends in exclusive cigarette or cigar use, exclusive marijuana use, any use of these products, and marijuana use among current cigarette or cigar users, were assessed among all students in the analytic sample overall, by sex, and by race/ethnicity. Data were assessed for the presence of linear trends using logistic regression analyses that adjusted for race/ethnicity, sex, and grade; p<0.05 was used to determine statistical significance. A significant linear trend indicated an overall increase or decrease during the study period. Data also were assessed for the presence of quadratic trends. A significant quadratic trend indicated a leveling off or change in direction of a trend line. Logistic regression models testing trends for students overall controlled for race/ethnicity, sex, and grade. Models among racial/ethnic subgroups controlled for sex and grade, models for sex subgroups controlled for race/ethnicity and grade. When a significant quadratic trend was found, Joinpoint software ¶ was used to identify the year in ). This analysis was restricted to non-Hispanic white, non-Hispanic black, and Hispanic students because of previously reported differences in the use of cigarettes, cigars, and marijuana by these groups. § Current use of cigarettes, cigars, or marijuana was assessed with the following respective questions: "During the past 30 days, on how many days did you smoke cigarettes?" "During the past 30 days, on how many days did you smoke any cigars, cigarillos, or little cigars?" and "During the past 30 days, how many times did you use marijuana?" Respondents with missing data for cigarette, cigar, or marijuana use questions were excluded from the analysis (9%). which the leveling off or change in direction occurred. Then logistic regression analyses were used to assess the presence of a significant linear trend in each segment.
During 1997-2013, linear decreases occurred in exclusive cigarette or cigar use among students overall, and among all sex and racial/ethnic subgroups (p<0.01), with an overall percentage decrease of 64% (Table) (Figure 1 ). Linear increases occurred in exclusive marijuana use among students overall, and among all sex and racial/ethnic subgroups, with an overall increase from 4.2% to 10.2% (p<0.01) (Table) . In addition, quadratic trends in exclusive marijuana use were identified among black and Hispanic students (p<0.01). Among black and Hispanic students, exclusive marijuana use did not change from 1997 to 2009 (9.2% to 10.9% and 5.9% to 8.5%, respectively), but increased from 2009 to 2013 (10.9% to 16.6% and 8.5% to 14.2%, respectively).
Linear decreases and quadratic trends occurred in any cigarette, cigar, or marijuana use among students overall, and among all sex and racial /ethnic subgroups (p<0.01) (Table) During 1997-2013, linear increases occurred in the proportion of cigarette or cigar users who used marijuana among students overall (51.2% to 62.4%), and among all sex and racial/ethnic subgroups (p for trend <0.01) (Figure 2 ). In addition, a quadratic trend was identified among black and Hispanic students (p<0.01). Among cigarette or cigar users, use of marijuana did not change among black students from 1997 to 2009 (63.7% to 66.4%) or Hispanic students from 1997 to 2007 (58.6% to 54.9%), but increased among black students from 2009 to 2013 (66.4% to 82.0%) and among Hispanic students from 2007 to 2013 (54.9% to 73.6%).
Discussion
From 1997 to 2013, a 64% percent decrease occurred in the percentage of U.S. white, black, and Hispanic high school students overall who used cigarettes or cigars exclusively. Additionally, among white students, any cigarette, cigar, or marijuana use decreased during the study period. Among black and Hispanic students, any cigarette, cigar, or marijuana use decreased from 1997 to 2007, but increased among black students from 2007 to 2013, and did not change for Hispanics from 2007 to 2013. Moreover, the percentage of white, black, and Hispanic students overall who were exclusive marijuana users more than doubled, and marijuana use among cigarette or cigar users also increased, with substantial increases identified among black and Hispanic students toward the end of the study period. Thus, public health advances in adolescent health resulting from lower cigarette and cigar use might be attenuated by increases in marijuana use, which vary by racial/ ethnic subgroup. Tobacco prevention and control strategies, including increasing tobacco product prices, adopting comprehensive smokefree laws, and implementing national public education media campaigns, have influenced the reduction in youth cigarette smoking.** Increases in marijuana use among U.S. youths might be attributable to decreasing perceptions of harm from 1991 to 2013 (from 78.6% to 39.5%). † † More specifically, decriminalization and legalization of recreational marijuana use in some states with minimal concomitant public health messaging to address potential detrimental health effects of marijuana use might be contributing to this perception (3). Further, legalization of medical marijuana use in 24 states, the District of Columbia, and Guam might increase perceptions of benefits of use, including that it is not harmful (4). § § Public health concerns about the recreational use of marijuana among adolescents is related, in part, to the potential for harm to individual users and the potential for marijuana to be a "gateway" to the use of tobacco and other illicit drugs or substances (1) . The amount of contaminants (e.g., tar and polycyclic aromatic hydrocarbons) inhaled from smoked marijuana can be more than double that of smoked tobacco (1). When marijuana is used concurrently with tobacco, the likelihood of individual-level harm, including cognitive, psychological, respiratory, and addiction problems, increases (1). The findings in this report are subject to at least five limitations. First, marijuana, cigarette, and cigar use were self-reported and not confirmed with biochemical tests, so the extent of underreporting or overreporting is unknown. Second, YRBS did not measure hookah use, which is an increasing mode of combustible tobacco use among youths, independently associated with marijuana use, and as such may offset declines in cigarette or cigar use (5,6). Third, YRBS did not measure use of electronic nicotine delivery systems such as e-cigarettes, hookahs, and vape pens (portable devices that function like e-cigarettes, but permit the user to add dry herbs, oils, or waxes) that are capable of aerosolizing marijuana (5,7). Fourth, YRBS did not measure blunt use, a popular product among youths and young adults, in which some or most of the tobacco in a cigar is taken out and replaced by marijuana (8) . Finally, these data apply only to white, black, and Hispanic youths who attended school and, therefore, are not representative of all persons in this age group. However, nationwide, in 2009, approximately 96% of persons aged 16-17 years were enrolled in a high school program (9) .
Reducing current use of cigarettes, cigars, and marijuana among U.S. youths might be achieved through multifaceted, targeted implementation of evidence-based program and policy interventions, in concert with active engagement of multiple stakeholders, including parents, schools, communities, and the media (10). Enhanced and sustained tobacco and marijuana use surveillance can help in monitoring trends and patterns of use, including the measurement of progress toward achieving Healthy People 2020 objectives ¶ ¶ related to the use of these substances among youth. Policy and programmatic efforts might benefit from approaches that focus on reducing the use of tobacco and marijuana among youth. 
Summary
Since 2010, the proportion of U.S. 12th grade students who reported using marijuana during the preceding 30 days (21.4%) has surpassed the proportion reporting use of cigarettes during the preceding 30 days (19.2%).
What is added by this report?
During 1997-2013, the proportion of white, black, and Hispanic high school students overall who were exclusive cigarette or cigar users decreased 64%, from 20.5% to 7.4%. The proportion of white, black, and Hispanic students who were exclusive marijuana users more than doubled from 4.2% to 10.2%, and among cigarette or cigar users, marijuana use increased, with considerable increases identified among black and Hispanic students toward the end of the study period.
What are the implications for public health practice? Despite significant declines since 1997, approximately 30% of white, black, and Hispanic U.S. high school students were current users of cigarettes, cigars, or marijuana in 2013. Policy and programmatic efforts might benefit from integrated approaches that focus on reducing the use of tobacco and marijuana among youths.
Ciguatera fish poisoning (CFP) is a foodborne illness acquired by eating predatory reef fish that have accumulated naturally occurring ciguatoxins found in several dinoflagellate (algae) species through their diet. CFP produces neuropsychiatric, neurologic, cardiovascular, and gastrointestinal signs and symptoms, and is one of the most commonly reported fishassociated marine intoxications. Ciguatoxin retains toxicity regardless of freezing or cooking. Prompt treatment can reduce debilitating neurologic symptoms that are associated with CFP. On November 3, 2014, the Florida Department of Health in Orange County (DOH-Orange) received a report through the DOH online foodborne illness complaint system from a person (patient A) describing paresthesias and numbness that suggested CFP, which had occurred on October 31, the day after eating two fish meals. The day the report was received, DOH-Orange interviewed patient A and determined that her illness met the CFP case definition. In Florida, a single case of CFP is considered an outbreak. Multiple data sources were used to identify five additional CFP cases. DOH-Orange, the DOH Bureau of Epidemiology, the Florida Department of Business and Professional Regulation (DBPR), the Florida Department of Agriculture and Consumer Services (DACS), and the U.S. Food and Drug Administration (FDA) collaborated to conduct investigations at two restaurants, one grocery store, two fish distributors, and one fish supplier to identify the outbreak food source. The six persons with CFP had eaten black grouper either at a local restaurant or purchased from a grocery store; the fish was traced back to a common international distributor. Rapid identification and reporting of CFP cases to public health officials is imperative to facilitate supportive medical care (1,2) and source-food traceback efforts.
The initial investigation by DOH-Orange identified patient A as an adult female non-Florida resident, who reported consuming mahi-mahi at restaurant A on October 30 at 3:00 p.m., and a black grouper filet at restaurant B at 7:45 p.m. the same day. No leftover fish was available from either meal. Patient A dined alone at restaurant A, but ate with three other persons at restaurant B. No food was shared at restaurant B, and although one other group member also consumed a separate black grouper filet, only patient A became ill. On October 31 at 3:00 a.m., approximately 7 hours after eating the grouper at restaurant B, patient A experienced acute onset of paradoxical temperature perception, paresthesias, extremity numbness, a metallic taste, nausea, vomiting, abdominal pain, diarrhea, arthralgia, and myalgia. A hotel physician evaluated the patient but did not provide a diagnosis. Patient A's signs and symptoms, including paradoxical temperature perception, paresthesias, fever, dizziness, nausea, vomiting, and diarrhea continued, and she reported her illness to the DOH online foodborne illness complaint system on November 3.
To identify additional associated CFP cases, DOH-Orange queried surveillance systems, including emergency department chief complaint records, poison control center reports, and reportable disease data through the Electronic Surveillance System for the Early Notification of Community-Based Epidemics-Florida (ESSENCE-FL), and reviewed foodborne illness complaints to DOH through phone, fax, and online report submission. On November 6, DOH-Orange received an automatic e-mail alert from ESSENCE-FL stating that on November 5, within a period of 22 minutes, four persons had visited one Orange County emergency department for "food poisoning." Review of medical records faxed the following day indicated the four persons all lived at the same local address and had symptoms of nausea, diarrhea, and vomiting. A notation that the patient had become ill after eating "bad fish" was found in all four medical records. No laboratory tests were ordered, and no medication was prescribed; the patients were discharged with diagnoses of gastroenteritis. On November 7, while DOH-Orange was interviewing the four ill patients, a fifth ill adult household member who had not sought medical attention was identified. All five household members (patients B, C, D, E, and F) shared a meal of black grouper fish heads on November 3. The fish heads were purchased from grocery store A on the same day they were consumed. The patients reported that symptoms began approximately 3 hours after the meal, and, in addition to the gastrointestinal symptoms reported in the hospital emergency department, they experienced other symptoms compatible with CFP, including paradoxical temperature perception, paresthesias, numbness, arthralgia, and myalgia. No leftover fish was available from the meal.
Among the six CFP cases identified in this outbreak, patients ranged in age from 36 to 64 years (median = 48 years), and four were male. The interval between consuming fish and symptom onset ranged from 3 to 7.25 hours (median = 3 hours). All patients experienced paradoxical temperature perception, nausea, paresthesias, numbness, abdominal pain, diarrhea, arthralgias, and myalgias ( were still symptomatic, with neurologic symptoms being most severe. Medical care was sought, and supportive care provided to five patients; however, no patients received intravenous mannitol, which has been reported to be effective in reversing the symptoms of CFP, particularly in severe cases (2, 3) .
Inspection of restaurant A, restaurant B, and grocery store A revealed that restaurant B and grocery store A had obtained the grouper from supplier A. Fish consumed by patient A at restaurant A was ruled out as the potential intoxicant vehicle because it is not commonly associated with ciguatoxin cases and was dissimilar to the other case exposures. An inspection of the facilities of supplier A found that the implicated lot of fish was received whole and then divided into filets that were provided to restaurant B and fish heads to grocery store A. Subsequent joint efforts by DOH-Orange, DBPR, DACS, and FDA traced the fish consumed by all persons who became ill to two distributors, through supplier A. The black grouper appears to have originated from Mexico. It was not possible to determine whether the implicated filet and any of the fish heads came from the same fish.
No leftover fish from the meals that caused the illnesses was available for laboratory analysis. Black grouper fish heads from the same lot that patients B-F consumed were collected from grocery store A. Testing by FDA did not detect ciguatoxin.
Discussion
No FDA-cleared or approved clinical tests for CFP are currently available. DOH defines a case of CFP as the occurrence of CFP-compatible symptoms (e.g., paradoxical temperature perception and paresthesia) in a person within 24 hours after ingestion of fish. Detection of ciguatoxin in the meal remnants is strongly suggestive of CFP but is not required for case confirmation.
This investigation made use of multiple surveillance systems and an online consumer complaint system to identify six persons with histories of fish consumption and signs and symptoms consistent with CFP, after eating black grouper, a species known to harbor ciguatoxin. Although CFP is a reportable disease in Florida, none of the five patients who sought medical care received a diagnosis of CFP, nor was suspected CFP reported to DOH by health care providers. The outbreak traceback investigation identified that the fish sold to the patients was purchased from two retail establishments (i.e., restaurant B and grocery store A) that received the fish from a common shipment to a single supplier through two distributors. Failure to detect ciguatoxin in FDA-tested fish heads samples taken from the same lot that intoxicated patients B-F is not inconsistent with the sporadic nature of the disease occurrence, or the observation that not all fish of a given species or from a given location are toxic (2) . For these reasons, food recalls are likely to be inefficient public health tools in response to CFP outbreaks.
During 2012-2014, a total of 137 CFP cases were reported in Florida, 109 (80%) of which were initially identified by surveillance and consumer complaint systems, 19 (14%) were reported by health care providers, and nine (7%) were reported via other, nondescribed methods. A health care provider diagnosis of CFP was documented for 73 (53%) cases. Although the early gastrointestinal symptoms associated with CFP are nonspecific, health care providers need to be educated to consider the diagnosis of CFP in patients with a clinically compatible illness and a history of fish consumption, to facilitate administration of ameliorative therapy and timely reporting to public health officials (3, 4) . Despite the fact that five of the six patients described in this report saw a health care provider, and at least four reported that they had eaten fish before becoming ill, the cases were only detected by DOH-Orange through an online self-reporting consumer complaint system and a syndromic surveillance system. Outbreak identification and associated public health efforts allowed for the education of the patients about CFP and the gathering of distribution and harvest data on the implicated fish. Avoiding consumption of large predatory reef fish from ciguatoxic-endemic areas, particularly the organs of these fish, which concentrate the toxin, can reduce the risk for CFP.
Summary
What is already known on this topic? Ciguatera fish poisoning (CFP), caused by the ingestion of predatory reef-dwelling fish harboring ciguatoxins is one of the most commonly reported fish-associated marine intoxications. Ciguatoxin retains toxicity regardless of freezing or cooking. Prompt treatment can reduce debilitating neurologic symptoms that are associated with CFP.
Syndromic surveillance systems in Florida identified six adults with CFP following consumption of black grouper. Five patients sought medical attention; health care providers did not make a diagnosis of CFP or report the cases to public health authorities, and none of the patients received treatment. Close collaboration among several investigating agencies allowed traceback efforts to link black grouper consumed by all patients to a common international distributor.
Syndromic surveillance systems capable of detecting CFP are essential public health tools to identify outbreaks and enhance investigations. Medical and public health practitioners should be educated to inquire about recent fish consumption when evaluating patients with clinically compatible signs and symptoms to allow for prompt treatment, and report suspected CFP cases to public health authorities to facilitate source-food traceback efforts. Public education on avoidance of consumption of relatively large predatory reef fish species known to be from ciguatoxic-endemic areas might reduce the risk for CFP.
The 2014-2015 Ebola virus disease (Ebola) outbreak in West Africa is the largest in history, and as of October 4, 2015, had claimed 11,297 lives in Guinea, Liberia, and Sierra Leone (1). On August 7, 2014, CDC first posted guidance on monitoring and movement of persons who might have been exposed to Ebola virus to prevent the spread of Ebola into the United States. Since that time, the Interim U.S. Guidance for Monitoring and Movement of Persons with Potential Ebola Virus Exposure (2) has been regularly updated based on the latest information available, most recently on May 13, 2015. On October 11, 2014, after the first case of Ebola was diagnosed in the United States, entry screening was implemented in five U.S. airports to identify travelers from countries with widespread Ebola transmission who might have been exposed to Ebola during the days before arrival or who had signs or symptoms of Ebola at the time of arrival (3).
On October 24, 2014, New York and New Jersey, both home to airports conducting entry screening, announced monitoring and movement policies for incoming travelers returning from Ebola-affected countries (4). The New York and New Jersey policies included mandatory quarantine for any person who had direct contact with a person with Ebola while in one of the Ebola-affected countries, including any medical personnel who had provided medical services for persons infected with Ebola, as well as active monitoring and possible quarantine for all persons with travel history to the affected countries, including those who had no direct contact with an infected person (4).
On October 27, 2014, CDC guidance was updated by establishing a "low (but not zero) risk" category; adding a "no identifiable risk" category; modifying the recommended public health actions in the high, some, and low (but not zero) risk categories; and adding recommendations for specific groups and settings (2) . Unlike the policies announced by New York and New Jersey, CDC guidance did not recommend mandatory quarantine. Instead, CDC guidance recommended active monitoring or direct active monitoring, and certain travel restrictions for symptomatic and some asymptomatic persons (2) . Within a few months after issuance of the updated CDC guidance in October 2014, states began announcing state-specific monitoring and movement policies or amending existing policies. Some of these policies included stricter requirements than those recommended in CDC's guidance. Because of concerns about the potential impact of inconsistencies between state and federal monitoring and movement policies, CDC's Public Health Law Program* assessed jurisdictional differences in guidance by systematically reviewing and evaluating publically available official Ebola screening, monitoring, and movement policies for each state and territory. These policies included executive orders, health orders, press releases, informational websites, and frequently asked questions (FAQ) resources. Each published policy was compared with CDC guidance to determine whether it was more or less restrictive than CDC guidance, equivalent to CDC guidance, unclear, or if no policy was publically available. Only policies contained on official government websites were examined, and the implementation of policies was not assessed.
Policies that require more extensive movement restrictions or more frequent reporting were considered more restrictive than CDC guidance, as were those that would place the traveler into a higher risk category than would CDC guidance. Policies that mirror CDC recommendations, or those that state that the jurisdiction follows CDC guidance, with no further articulation as to how that state's monitoring and movement policies were being implemented, were considered equivalent to CDC guidance. Policies were considered less restrictive than CDC recommendations if they require asymptomatic persons to undergo public health actions that are less stringent than CDC's recommendations, such as permitting all travelers from Ebola-affected countries to return to work regardless of risk level. Policies were considered to be unclear if they were ambiguous regarding the categorization, monitoring, and movement of persons, including policies that state that movement restrictions would be implemented on a case-by-case basis, or that link to CDC guidance, without indicating whether the jurisdiction was following this guidance, or simply providing the resource for informational purposes. If no policy could be found on any publically available websites managed by government authorities, that state or territory was considered to have no published policy.
As of August 31, 2015, a total of 17 states and the District of Columbia had policies that were more restrictive than current CDC guidance, 35 states and territories had policies that were equivalent to CDC guidance, no states or territories had policies that were less restrictive than CDC guidance, one territory had an unclear policy, and two territories did not have a publicly available monitoring and movement policy (Figure) . † The results were published online as the Interim Table of State Ebola Screening and Monitoring Policies for Asymptomatic Individuals (5) . Although states have the prerogative to set their own public health policies under the police powers reserved to them by the 10th Amendment of the U.S. Constitution (6), the differences in policies have the potential to create confusion among members of the public, persons considering whether to join the response effort, and responders returning from West Africa (7). Confusion can be minimized when states make their policies clear and readily accessible to the public. Cervical cancer, caused by human papillomavirus (HPV), is the leading cause of cancer mortality among women in Botswana (1). Three vaccines prevent infection with HPV types responsible for the majority of cervical cancer worldwide. Two of these vaccines also protect against types that cause anogenital warts. Two vaccines are currently prequalified by the World Health Organization (WHO); these were >90% efficacious in preventing precancerous lesions caused by HPV types 16 and 18 (the cause of 70% of cervical cancers) in clinical trials studying women who received the recommended 3-dose series before exposure to targeted HPV types. WHO recommends targeting HPV vaccination to girls aged 9-13, before initiation of sexual activity and thus HPV exposure (2) . This report summarizes HPV vaccination coverage among girls aged ≥9 years enrolled in grades 4-6 in 23 primary schools in Molepolole, Botswana, during a 2013 HPV vaccination demonstration project conducted by the Botswana Ministry of Health (MOH). Of the 2,488 eligible school girls, 83% received the first dose and 79% completed the 3-dose HPV vaccination series. Drop out between first and third dose was 5%. No serious adverse events were reported. Given the successful pilot, the project was expanded to immunize approximately 6,000 girls in 2014, followed by national rollout of the HPV vaccine in 2015.
Botswana is an upper middle income country with a population of 2 million in southern Africa. Approximately 22,000 females are born annually. Human immunodeficiency virus (HIV) prevalence among women aged 15-49 years is 28%.* Cervical cancer, the fourth most common cancer worldwide (3), is the most common cancer among women aged 15-44 years and the leading cause of cancer mortality among women in Botswana, reflecting the 4-5 times increased risk for cervical cancer among HIV-infected women (3). Primary prevention of cervical cancer via HPV vaccination might be particularly beneficial to Botswana, given the country's challenges with both HIV infection and cervical cancer. However, establishing a sustainable program to deliver HPV vaccine to a population not previously targeted for immunizations can be challenging in resource-limited countries.
In 2012, the Botswana MOH initiated its National Cervical Cancer Prevention Program Comprehensive Strategy (2012) (2013) (2014) (2015) (2016) . The same year, the Pink Ribbon Red Ribbon (PRRR) initiative, a public-private partnership for breast and cervical cancer prevention and treatment, was implemented to expand cervical cancer screening and treatment with a focus on HPV-related disease. With PRRR and other donor support, the Botswana MOH decided to conduct a grade-based HPV vaccination demonstration project in primary schools. The project was completed during the 2013 school year (JanuaryDecember) in Molepolole, a town with a population of 63,000 located 31 miles (50 kilometers) from the national capital. The objectives were to evaluate HPV vaccine implementation among age-eligible girls enrolled in school and to improve planning for possible expansion of HPV vaccine activities.
A multidisciplinary team, with representatives from the Botswana MOH, including Expanded Program on Immunization, Ministry of Education, WHO, nongovernmental organizations, and other key stakeholders, developed the project protocol, educational materials, a parental consent form, and data-gathering tools. The Botswana MOH determined the project to be public health practice. Multiple educational meetings for community stakeholders, sensitization meetings for parents and educators, and training sessions for local public health providers participating in the project were held before implementation. All girls aged ≥9 years attending grades 4-6 at any of Molepolole's 17 public primary schools, five private primary schools, or one school for special needs students, and who had written parental consent, were eligible for vaccination. Participating schools provided enrollment lists of female students. The quadrivalent HPV vaccine, Gardasil (Merck and Co.), was administered in schools by public health workers in March, May (approximately 2 months after the first dose), and early October 2013 (approximately 6 months after the first dose). Immunization teams visited each school twice during each of the three vaccination campaign rounds. Girls who missed a dose at school could receive it at Scottish Livingston Hospital in Molepolole. Vaccination data on each girl were collected on paper-based records and transferred to a spreadsheet. To identify the number of girls who received HPV vaccination during March-December 2013, staff reviewed the line lists of girls by school, which contained birthdate, grade, documentation of parental consent, and HPV vaccination date.
Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project -Botswana, 2013
There were 2,742 girls registered in grades 4-6 in the 23 participating schools (median enrollment = 135 girls; range = 12-227 girls). Of the 2,590 (94%) girls with a recorded date of birth, 2,488 (96%) were aged ≥9 years on the first day of school vaccination in March 2013. Among these girls, 83% (n = 2,075) received the first dose, 82% (n = 2,049) received 2 doses, and 79% (n = 1,967) completed the 3-dose series (Table) . Overall vaccination completion among girls who received the first dose was 95%. Approximately one fifth (431/2488) of girls with known date of birth were without documented parental consent, 88 of whom received vaccination. The proportion of school girls vaccinated increased with increasing age (Cochran-Armitage trend test p<0.001) and was higher among girls who attended public school compared with those who attended private school (p<0.001). Passive surveillance for adverse events (following girls for 30 days postimmunization) was designed for this campaign. No serious adverse events were reported.
Discussion
HPV vaccines are safe and highly efficacious (4); postlicensure monitoring data from countries with high vaccination coverage indicate population-level impact against early cervical disease caused by targeted HPV types, further supporting these results (5). The vaccines' potential impact is likely to be greatest in countries with less established cervical cancer screening programs and high disease levels, such as Botswana; however, delivering a multidose vaccine to adolescent girls is challenging and has impeded large scale introduction in lowresource countries.
The 79% 3-dose vaccination coverage achieved in this project is comparable to that attained in an HPV vaccination project conducted in the Mwanza Region, Tanzania (76.1%), but lower than the vaccination coverage in school-based demonstration projects in KwaZulu Natal province, South Africa (97.8%) (6, 7) . Approximately all doses were administered on time and at schools. Similar to the Tanzania demonstration project, the vaccination rate was higher in public than in private schools (6) .
The findings in this report are subject to limitations. Out-ofschool preadolescent girls were not represented in the estimated vaccination coverage; thus vaccination coverage is likely overestimated for the general population of girls aged 9-13 years. WHO recommends use of population-based data to identify all eligible girls in the population by year of age. † In this project, the number of out-of-school girls in the Molepolole catchment area was not available. However, an estimated 15% of primary school-aged girls were out-of-school in Botswana in 2009 (8) . Vaccination coverage might have been underestimated because of incomplete documentation of doses administered at Scottish Livingston Hospital, or because the analysis excluded girls without recorded birthdates who were immunized. The scalability and sustainability of the HPV vaccination strategy used in this demonstration project were not assessed.
Programmatic challenges and expense of the 3-dose HPV vaccination series led to global interest in a 2-dose HPV vaccine schedule (0, 6-12 months). By using data from noninferiority immunogenicity trials and postlicensure studies of both vaccines, in April 2014, WHO recommended a 2-dose schedule for immunization of immunocompetent girls aged 9-14 years for either vaccine at 0, 6-or 0, 12-month intervals (2) . The full 3-dose series remains recommended for girls aged ≥15 years, for those who are immunocompromised, or whenever interval between the first 2 doses is <6 months.
Demonstration projects are valuable to identify and address challenges, build necessary partnerships across government agencies and with other stakeholders, and gauge political support before implementing a national vaccination program. Although Botswana's demonstration project successfully achieved high vaccination coverage among girls enrolled in school, problems with implementation occurred. At campaign initiation, certain grade 4 girls were aged <9 years, precluding complete vaccination of grade 4 girls through this project. signed consents, and 2) lower vaccination rates, despite robust precampaign community sensitization efforts. On the basis of the 2013 challenges, Botswana's 2014 HPV vaccination project was modified to target grades 5-7 and replaced formal written consent with an implied consent process (9) .
The national HPV vaccine rollout in 2015 employed a 2-dose vaccination schedule. Recent post hoc analysis of data from two large vaccine trials reported that women aged 15-25 years who received a single dose of HPV vaccine were protected against HPV types 16 and 18 for 4 years after vaccination (10) . In Botswana, concerns still being discussed include how best to provide vaccinations to out-of-school girls; the best venue for delivering vaccine (school versus health care facility); and how to provide a third dose to girls who are HIV-infected (HIV prevalence among girls aged 10-14 years is 4.4% in Botswana), aged ≥15 years, or received the first 2 doses <6 months apart. From December 1, 2014, to January 30, 2015, in King County, Washington, four cases of ocular syphilis, defined as clinical signs or symptoms consistent with ocular disease (e.g., uveitis or vision loss) in a person with laboratory-confirmed syphilis of any stage, were reported. All four cases occurred in men who have sex with men (MSM), two of whom were sex partners. Median age of the four patients was 39 years (range = 29-52 years). Three of the patients were infected with human immunodeficiency virus (HIV). Among the three HIVinfected patients, the median CD4 count was 111 cells/ml, and the median HIV-RNA was 34,740 copies/ml. All four patients had visual symptoms, including vision loss, flashing lights, and blurry vision. Ophthalmologic examinations were performed and all four were diagnosed with uveitis. All four patients had positive serum from rapid plasma reagin (RPR) testing (titer range = 1:256-1:4096). Based on history, one patient had late latent syphilis, and the remaining three received diagnoses of early latent syphilis. The three patients with early latent syphilis had cerebrospinal fluid (CSF) analysis performed; two had positive CSF in venereal disease research laboratory (VDRL) testing. Three patients received treatment with aqueous crystalline penicillin G for 14 days, and one was treated with 10 days of procaine penicillin and probenecid. All four patients had initial improvement in ocular symptoms after treatment. However, one patient still had a blind spot in one eye 1 month after treatment, and two patients were considered legally blind after 5 months; the fourth patient was lost to follow-up.
Public Health-Seattle & King County has estimated that approximately 6-12 cases of symptomatic ocular syphilis occur annually in the county (1). The occurrence of four cases within 2 months led to a clinical advisory to medical providers and west coast health departments.
Following the clinical advisory from King County, the San Francisco Department of Public Health identified eight cases of ocular syphilis reported from December 15, 2014, to March 25, 2015. Seven cases (88%) were in males; six (75%) were in MSM. No epidemiologic links were identified among the patients. Median age of the patients was 52 years (range = 35-58 years). Seven (88%) were HIV-infected (six MSM and one female commercial sex worker). Four patients had CD4 and HIV-RNA lab data available; median CD4 count was 291 cells/ml, median HIV-RNA was 84,500 copies/ml. Ophthalmologic examinations were performed on all eight patients, and records were reviewed for five. Diagnoses included ischemic optic neuropathy, uveitis, and retinal detachment. All patients had positive serum RPR (titer range = 1:256-1:8192); two had an initial false negative RPR because of the prozone effect. Three patients had a rash consistent with secondary syphilis, four had early latent syphilis, and one had late latent syphilis. Four cases had CSF analysis, three with a positive CSF VDRL result. All eight patients received aqueous crystalline penicillin G for 14 days. Following treatment, seven patients had improvement in ocular symptoms, and one patient had permanent visual loss in one eye after 3 months.
Ocular syphilis, a clinical manifestation of neurosyphilis, typically occurs during early syphilis; uveitis is the most common presentation (2-4). For sexually active persons, the following steps can reduce the risk for syphilis: 1) being in a long-term mutually monogamous relationship with a partner who has been tested and has not tested positive for early syphilis; 2) using latex condoms correctly every time they have sex; and 3) for MSM, having annual screening for syphilis, and more frequent screening for MSM at greater risk. All patients who receive a diagnosis of syphilis should be asked screening questions to identify visual, hearing, or neurologic symptoms and receive a careful neurologic exam. Patients with ocular symptoms consistent with syphilis should be serologically evaluated for syphilis. An immediate ophthalmologic evaluation and CSF examination is recommended for patients with syphilis and ocular complaints. However, a normal CSF examination can occur with ocular syphilis. Ocular syphilis cases should be managed according to the treatment recommendations for neurosyphilis, regardless of CSF results, and patients should be tested for HIV (5) .
Cases of ocular syphilis should be reported to the state or local health department within 24 hours of diagnosis (6) . For questions about possible ocular syphilis cases please contact Sara E. Oliver, MD, at 404-639-1204 or at yxo4@cdc.gov. During 2004-2013, the number of teens aged 13-19 years who died in motor vehicle crashes declined by 55% from 5,645 to 2,524 (1). During the same period, the rate of passenger vehicle drivers aged 16-19 years involved in fatal crashes decreased 56%, from 34.7 to 15.1 per 100,000 persons (1). Despite these encouraging trends, motor vehicle crashes remain the leading cause of death for teens.
Graduated driver licensing (GDL) is widely credited with contributing to declines in teen crash fatalities. Evaluations of GDL have demonstrated a 20-40% reduction in crash risk for the youngest drivers (2) . GDL provides longer practice periods, limits driving under high risk conditions for newly licensed drivers, and requires greater participation of parents in their teens' learning-to-drive process.
Research indicates that more comprehensive GDL systems prevent more fatal crashes compared with less comprehensive GDL systems (3) (4) (5) . These systems include provisions, such as: a minimum age of 16 years for learners' permits; a mandatory holding period of at least 12 months for learners' permits; nighttime driving restrictions between 10:00 p.m. and Table) indicate that, despite having the lowest overall rates, the highest rate of increase in deaths involving opioid analgesics was among those under 15 years of age (RR = 3.7), followed by those 65-84 years of age (RR = 3.6). Whites, females, and those residing outside of NYC also showed higher rates of increase in opioid analgesic-related mortality (RR = 2.8, 2.9, and 3.9, respectively)."
The second sentence of the fifth paragraph should read as follows: "Deaths per 100,000 among all New York state residents not enrolled in Medicaid increased from 1.18 in 2003 to 2.82 in 2012, while among Medicaid enrollees, the rates increased from 3.48 in 2003 to 8.31 over the same period."
On page 379, the last sentence of the first paragraph should read as follows: "Consistent with the national trend (5), the rate of increase, as indicated by the rate ratios, is slightly higher in New York state among women than among men (RR = 2.9 and 2.4, respectively)."
It is stated in several places in the report that rates of opioid analgesic-related mortality in New York state were consistently higher among residents who lived outside New York City (NYC). After correction of certain data, it was found that these rates were higher among those residing outside of NYC during 2007-2012, but the rates were lower among those residing outside of NYC during 2003-2006.
On page 378, in the Abbreviation: NYC = New York City.
* With 95% confidence intervals indicated with error bars. † Based on responses to the question, "Has a doctor or health professional ever told you that [child] had attention-deficit/hyperactivity disorder (ADHD) or attention deficit disorder (ADD)?" § Poverty status is based on family income and family size using the annually updated U.S. Census Bureau poverty thresholds. Family income was imputed when missing. ¶ Estimates are based on household interviews of a sample of the noninstitutionalized U.S. civilian population and are derived from the National Health Interview Survey's sample child component.
During 2011-2014 approximately 10% of all children aged 5-17 years were reported by parents to have been diagnosed with ADHD. The percentage of children who had ever been diagnosed with ADHD was significantly higher among boys (14%) than among girls (6%) overall and within each poverty status category. Among both boys and girls, poor children (i.e., those living in families with incomes <100% of the poverty level) were more likely to have been diagnosed with ADHD than children living in families with incomes ≥400% of the poverty level. 
